Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases.

19 , 21 In addition, an earlier report showed that CDKN2C haploinsufficiency is associated with a strong trend toward reduced progression-free survival in RET -mutated MTC treated with systemic therapy. 21 However, this relationship has not been studied in patients receiving selective RET inhibitors, to our knowledge, and the significance of CDKN2C loss in this setting remains to be determined.

also in 5,725 other papers